182 related articles for article (PubMed ID: 16309912)
1. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
2. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
[TBL] [Abstract][Full Text] [Related]
3. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
[TBL] [Abstract][Full Text] [Related]
4. Tricyclic pharmacophore-based molecules as novel integrin alphavbeta3 antagonists. Part IV: preliminary control of alphavbeta3 selectivity by meta-oriented substitution.
Kubota D; Ishikawa M; Ishikawa M; Yahata N; Murakami S; Fujishima K; Kitakaze M; Ajito K
Bioorg Med Chem; 2006 Jun; 14(12):4158-81. PubMed ID: 16504518
[TBL] [Abstract][Full Text] [Related]
5. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.
Yan Y; Li Y; Zhang S; Ai C
J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
[TBL] [Abstract][Full Text] [Related]
7. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
[TBL] [Abstract][Full Text] [Related]
9. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
Su T; Naughton MA; Smyth MS; Rose JW; Arfsten AE; McCowan JR; Jakubowski JA; Wyss VL; Ruterbories KJ; Sall DJ; Scarborough RM
J Med Chem; 1997 Dec; 40(26):4308-18. PubMed ID: 9435900
[TBL] [Abstract][Full Text] [Related]
11. N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.
Xi N; Arvedson S; Eisenberg S; Han N; Handley M; Huang L; Huang Q; Kiselyov A; Liu Q; Lu Y; Nunez G; Osslund T; Powers D; Tasker AS; Wang L; Xiang T; Xu S; Zhang J; Zhu J; Kendall R; Dominguez C
Bioorg Med Chem Lett; 2004 Jun; 14(11):2905-9. PubMed ID: 15125957
[TBL] [Abstract][Full Text] [Related]
12. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
13. GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted beta-amino acid derivatives, and a substituted benzamidine structure.
Hayashi Y; Katada J; Harada T; Tachiki A; Iijima K; Takiguchi Y; Muramatsu M; Miyazaki H; Asari T; Okazaki T; Sato Y; Yasuda E; Yano M; Uno I; Ojima I
J Med Chem; 1998 Jun; 41(13):2345-60. PubMed ID: 9632368
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
15. Design of a new class of orally active fibrinogen receptor antagonists.
Klein SI; Molino BF; Czekaj M; Gardner CJ; Chu V; Brown K; Sabatino RD; Bostwick JS; Kasiewski C; Bentley R; Windisch V; Perrone M; Dunwiddie CT; Leadley RJ
J Med Chem; 1998 Jul; 41(14):2492-502. PubMed ID: 9651154
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.
Penning TD; Khilevich A; Chen BB; Russell MA; Boys ML; Wang Y; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Rader RK; Settle SL; Shannon KE; Steininger CN; Westlin MM; Westlin WF
Bioorg Med Chem Lett; 2006 Jun; 16(12):3156-61. PubMed ID: 16621534
[TBL] [Abstract][Full Text] [Related]
17. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
[TBL] [Abstract][Full Text] [Related]
18. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR
J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962
[TBL] [Abstract][Full Text] [Related]
19. Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists.
Malovichko OL; Petrus AS; Krysko AA; Kabanova TA; Andronati SA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2006 Oct; 16(20):5294-7. PubMed ID: 16919941
[TBL] [Abstract][Full Text] [Related]
20. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.
Bassler N; Loeffler C; Mangin P; Yuan Y; Schwarz M; Hagemeyer CE; Eisenhardt SU; Ahrens I; Bode C; Jackson SP; Peter K
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):e9-15. PubMed ID: 17170374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
